Renal Denervation May Be Beneficial After All

Two studies demonstrate short-term reductions in blood pressure in patients on and off medications.

Catheter-based renal denervation (RD) to treat hypertension (HTN) looked promising in early feasibility studies, but subsequent randomized trials had inconsistent results. In two small, randomized, sham-controlled, manufacturer-funded trials, researchers re-examined this therapy in patients on and off medications.

Utilizing an endovascular balloon and ultrasound thermal energy for ablation, the RADIANCE-HTN SOLO (NCT02649426) investigators enrolled 146 nonmedicated patients (mean age, 54; 42% women) with mild-to-moderate HTN (range, 135/85 to 170/105 mm Hg). The primary endpoint, daytime ambulatory systolic blood pressure (SBP) at 2 months, was reduced significantly more with RD than with sham treatment, by 6.3 mm Hg. Decreases of ≥5 mm Hg w…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)